A Clinical Trial of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Phase 3
675
about 6.8 years
18+
7 sites in AL, CT, FL +4
What this study is about
This trial is testing if it medicines MK-1084 and subcutaneous pembrolizumab can be used to treat non-small cell lung cancer when given together. The goal is to learn if people who receive MK-1084 with subcutaneous pembrolizumab live longer without the cancer growing or spreading than in people who receive subcutaneous pembrolizumab with chemotherapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Pembrolizumab (+) Berahyaluronidase alfa
- 2.Take Carboplatin
- 3.Take Cisplatin
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), pemetrexed
injection, intravenous, infusion, injection (Injection)
Primary: Progression Free Survival (PFS) in Participants with Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%
Secondary: Change from Baseline in Chest Pain Score (Item 40) on the EORTC QLQ-LC13, Change from Baseline in Cough Score (Item 31) on the European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire (EORTC QLQ-LC13), Change from Baseline in Dyspnea Score (Item 8) on the EORTC QLQ-C30, Change from Baseline in Global Health Status/Quality of Life (GHS/QoL) (Items 29, 30) on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30), Duration of Response (DOR), Number of Participants Who Discontinued Study Treatment Due to an AE, Number of Participants Who Experienced One or More Adverse Events (AEs), ORR in Participants with PD-L1 TPS ≥1%
Oncology